The inventory of Danish biotech Novo Nordisk was down 1.6% premarket Tuesday, after a examine discovered that the corporate’s weight problems drug Wegovy lags its foremost rival, Eli Lilly & Co. Inc.’s Mounjaro, in velocity and magnitude of weight reduction.
Novo Nordisk’s inventory slumps after examine finds Wegovy lags Lilly’s Mounjaro in velocity and scale of weight reduction
